A study conducted by Laura Bukavina, MD, MPH, MSc, and colleagues published in JCO Oncology Practice investigated financial distress across genitourinary (GU) cancer survivors, with a focus on prostate, kidney, and bladder cancers. Researchers focused on the economic impact of disparities related to insurance coverage and its associations with the material, psychological, and behavioral elements of financial distress. They noted that financial distress included subjective difficulties faced by patients, including emotional and psychological struggles. ...
Renal Cell Carcinoma
Advertisement
Latest News
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
The group discusses how blocking ACSS2 may affect immune cells in the tumor microenvironment. Drs. Beckermann, Rathmell, and Bacigalupa highlight the potential of ACSS2 as a therapeutic target in kidney cancer.
CEUS for the assessment of nccRCC can provide a more sensitive alternative to conventional ultrasound imaging.
The primary end point was ORR according to Immune Response Evaluation Criteria in Solid Tumors at 4 months.
The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.